Use of macrolide compounds for treating glaucoma

a technology of macrolide compounds and glaucoma, which is applied in the direction of heterocyclic compound active ingredients, biocide, drug compositions, etc., can solve the problems of loss of vision and the inability to clearly understand the mechanism by which the damage occurs

Inactive Publication Date: 2002-05-07
ASTELLAS PHARMA INC
View PDF1 Cites 42 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented inventor describes how certain types of drugs called macrolides have been found that could help treat diseases such as cancer by acting on specific molecules within cells involved in cell growth processes like DNA replication. These specialized small chemical substances were mixed into medicines made from these materials before being given them through different routes. They worked effectively against various forms of tumors caused by viruses or bacteria.

Problems solved by technology

The technical problem addressed in this patented text relates how to improve the efficiency or effectiveness of an electronic device by improving its performance without adding extra components like memory chips that can be expensive for manufacturers who want it at all costs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of macrolide compounds for treating glaucoma
  • Use of macrolide compounds for treating glaucoma
  • Use of macrolide compounds for treating glaucoma

Examples

Experimental program
Comparison scheme
Effect test

example 1

The FK 506 Substance (1 g) was dissolved in ethanol (10 ml), and thereto was added hydroxypropyl methyldlellulose 2910 (TC-5R) (1 g) to prepare a suspension. To this suspension was added dichloromethane (5 ml) to prepare a homogeneous solution. Lactose (2 g) and croscarmellose sodium (Trade Mark: Ac-Di-Sol, maker: Asahi Chemical industry) were homogeneously suspended to this solution, and then the organic solvent was removed by evaporation. The residual product was dried under reduced pressure for 10 hours by vacuum dryer, milled for 2 minutes by coffee mill and then passed through a sieve (32 mesh) to give the solid dispersion composition of FK 506 Substance (5 g). This composition was capsulated by a conventional manner to provide capsules containing 1 mg or 5 mg of FK 506 Substance per each capsule.

example 2

An aqueous suspending eye drop containing the above-mentioned ingredients is prepared according to a conventional manner shown in EP-A-0406791, the disclosure of which is incorporated herein by reference.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Acidityaaaaaaaaaa
Pressureaaaaaaaaaa
Login to view more

Abstract

Macrolide compounds, such as the FK506 Substance and its related compounds, are provided for the prevention or treatment of eye diseases, particularly glaucoma. Composition containing such compounds is also disclosed.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products